Profusa Shareholders Approve Massive Dilution for Acquisition, New Reverse Split Authority, and Equity Plan Increase

summarizeSummary

Profusa shareholders approved a new reverse stock split authorization, the issuance of highly dilutive convertible preferred stock for a $30 million acquisition, and an increase in the equity incentive plan, signaling significant future dilution and ongoing financial challenges.

check_boxKey Events

• Reverse Stock Split Authorization Approved

  Shareholders authorized the Board to effect one or more reverse stock splits at a ratio of 1-for-5 to 1-for-200 over the next two years. This follows a 1-for-75 reverse split in February 2026, indicating continued efforts to meet Nasdaq listing requirements.

• Bio Insights Acquisition Dilution Approved

  Approval was granted for the issuance of convertible preferred stock and common stock upon conversion to Bio Insights LLC as consideration for the $30 million acquisition of PanOmics Assay know-how. This represents massive potential dilution relative to Profusa's current market capitalization.

• NorthView Promissory Note Conversion Approved

  Shareholders approved the potential issuance of common stock exceeding 19.99% of outstanding shares upon conversion of a promissory note to NorthView Sponsor I LLC, enabling further dilution from a prior financing.

• Equity Incentive Plan Expansion Approved

  The company's 2025 Equity and Incentive Plan was amended to increase the number of shares available for issuance by 695,544, bringing the total to 795,930 shares, representing 15% of outstanding common stock.

auto_awesomeAnalysis

Shareholders have approved several critical proposals that will lead to substantial dilution and signal ongoing financial distress for Profusa. The approval of a new reverse stock split authorization (up to 1-for-200) comes shortly after a 1-for-75 split, indicating persistent challenges in maintaining Nasdaq listing requirements. Furthermore, the approval to issue convertible preferred stock for the $30 million Bio Insights acquisition is highly dilutive, especially given the company's current market capitalization of less than $1 million. Approvals for issuing shares related to a prior dilutive promissory note and a significant increase in the equity incentive plan further compound the potential dilution for existing shareholders. These actions are necessary for the company's operations and acquisition strategy but come at a very high cost to equity holders.